Forest/Lipha Campral Clears FDA; Part of Alcoholism Management Program
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA clears acamprosate as alcoholism maintenance therapy. The drug may not be effective in patients who are actively drinking at the start of treatment, the agency says.
You may also be interested in...
Forest Launches Alcoholism Drug Campral Through Antidepressant Sales Reps
Lipha/Forest's alcoholism treatment Campral (acamprosate) will be available at an average wholesale price of about $4.36 per day
Forest Launches Alcoholism Drug Campral Through Antidepressant Sales Reps
Lipha/Forest's alcoholism treatment Campral (acamprosate) will be available at an average wholesale price of about $4.36 per day
Forest To Launch Alcoholism Treatment Campral By Year-End
The company will use the portion of its antidepressant sales force already detailing alcohol treatment facilities to market the drug. Forest plans to work with psychiatrists and treatment groups to develop an alcoholism management program that includes Campral.